Evidence map›Paper›PMID 41222620›Full record

ReviewEpigenomics2026

5mC and 5hmC methylation sequencing: the power of 6-base sequencing in a multiomic era.

Robert Crawford, Tom Charlesworth, Stephen Riffle, Kurt Yardley, Robert Osborne

Abstract readReview
In one paragraph

Review in Epigenomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. "Updates on diagnostic and prognostic molecular biomarkers of CNS tumors".Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Robert Crawfordbiomodal Ltd, Chesterford Research Park, Saffron Walden, UK.ORCID 0009-0003-2487-4626
Tom Charlesworthbiomodal Ltd, Chesterford Research Park, Saffron Walden, UK.ORCID 0000-0001-9233-7679
Stephen RiffleIndependent Consultant, Denver, CO, USA.ORCID 0000-0002-5947-242X
Kurt Yardleybiomodal Ltd, Chesterford Research Park, Saffron Walden, UK.
Robert Osbornebiomodal Ltd, Chesterford Research Park, Saffron Walden, UK.ORCID 0000-0002-1914-1239

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The integration of genetic and epigenetic information is essential for a comprehensive understanding of genome function and regulation. Traditional sequencing methods often fall short in capturing both genetic variants and epigenetic modifications such as 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) simultaneously. Recent advances in 6-base sequencing have enabled the simultaneous, base-resolution detection of canonical bases and key cytosine modifications in a single workflow. This review explores the biological significance of 5mC and 5hmC, discusses current methods to achieve 6-base sequencing, and highlights recent applications in academic and clinical settings.

Indexed as

5-MethylcytosineDNA MethylationEpigenomicsSequence Analysis, DNAAnimalsEpigenesis, GeneticHigh-Throughput Nucleotide SequencingHumans5-hydroxymethylcytosine5-Methylcytosine5hmC5mC6-base sequencingDNA methylationepigeneticsGeneticsmodCWGBS

Identifiers

PMID41222620
PMCPMC12826727

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.